Franklin Genomic Adv ETF

Medpace Holdings CEO Announces Sale of Common Stock

Legal & General Group Increased Stake in BridgeBio Pharma

Guardant Health insiders sold $5.846 million worth of shares

Guardant Health Exec Monroe Terilyn J Sells $5.8M in Shares

Natera Inc. CEO Disposes of Common Stock

Natera's Clinical Diagnostics President Reports Sale of Ordinary Shares

Insmed Inc. CMO Reports Disposition of Common Stock

Natera Inc. showcases new data for Signatera™ at ASH annual meeting

Panagora Asset Management Inc. Increases Holdings in Unity Therapeutics by 340.8%

United Therapeutics Corp Chairman Rothblatt Sells $3.9 Million in Stocks

CEO of Joint Therapy Corp Disposes of Common Stocks

Natera to Present Signatera Detection Data at San Antonio Breast Cancer Symposium

Medpace CEO Sells Company Shares

CEO Martin A Rothblatt of United Therapeutics disposed of common stock

Loomis Sayles Reduces Stake in Natera, Stock Rises

Intech Investment Management LLC Reduces Holdings in Natera Inc.

F m Investments LLC Reduces Holdings in Insmed, Inc.

Rockefeller Capital Management Increases Stake in Guardant Health

Natera Director Roelof Botha Reports Sale of Company Shares

Elizabeth M. Anderson Reports Sale of Insmed Inc. Common Stock

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

Guardant Health, Inc.'s common stock is subject to a lock-up agreement ending on December 5, 2025. The lock-up period lasts 31 days, from November 4 to December 5, 2025. During this time, directors and executive officers cannot sell or transfer shares without consent from Goldman Sachs & Co. LLC and Jefferies LLC, with specified exceptions.

marketscreener

Guardant Health

Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.

ADPT

Officer Robins Harlan S of Adaptive Biotechnologies Corp filed a Form 144 with the SEC to sell 10,000 shares on December 4, 2025, through Goldman Sachs & Co, under a prearranged trading plan (10b5-1).

Reuters

Adaptive Biotechnologies

Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT]

INSM

Lewis William H, Chairman of Insmed Inc, filed a Form 144 with the SEC to sell 10,699 shares on December 4, 2025, through Merrill Lynch & Co Inc. The sale is executed under a prearranged trading plan (10b5-1).

Insmed

Chmn Lewis Files To Sell 10,699 Of Insmed Inc [INSM]

MEDP

August J. Troendle, CEO and Director of Medpace Holdings Inc., reported the sale of common shares. This information was published via EDGAR by the U.S. Securities and Exchange Commission. The news is generated by Public Technologies using AI and is for informational purposes only.

Medpace

Medpace CEO August J. Troendle Reports Sale of Common Shares

UTHR

Martine A. Rothblatt, Chairman of United Therapeutics Corp, filed a Form 144 with the SEC to sell 4,000 shares on December 4, 2025, through TD Securities (USA) Inc. The sale is executed under a prearranged trading plan (10b5-1).

United Therap

Chmn Rothblatt Files To Sell 4,000 Of United Therapeutics Corp [UTHR]

ALNY

Alnylam Pharmaceuticals (ALNY) stock has surged 12% in the past month and nearly doubled over the past year, raising questions about its valuation. The stock is priced at $473, slightly below Wall Street's target of $489, suggesting a modest 3.2% undervaluation. However, a DCF model indicates a 21% undervaluation with a fair value near $601. The growth is driven by AMVUTTRA's uptake and RNAi therapies' market expansion. Risks include pricing pressure and high R&D costs. Investors are advised to consider other innovative healthcare stocks.

Simplywall

Alnylam Pharma

Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation?

Insmed Inc. announced inducement awards to 92 new employees under its 2025 Inducement Plan. The awards include 44,273 restricted stock units and options to purchase 2,490 shares at $207.77 per share. The stock units vest over four years, contingent on continued employment. This announcement was made via PR Newswire on December 4, 2025.

Insmed Grants Inducement Awards to 92 New Employees Under 2025 Plan

BBIO

Legal & General Group Plc increased its holdings in BridgeBio Pharma by 17.5% in Q2, owning 159,573 shares worth $6.89 million. Analysts have raised price targets for BridgeBio Pharma, with Wells Fargo, Goldman Sachs, JPMorgan, Cowen, and Cantor Fitzgerald giving positive ratings. The stock opened at $74.15, with a market cap of $14.29 billion. Insider trading includes sales by Directors Hannah Valantine and Andrew Lo.

Market Beat

Bridgebio Pharma

Legal & General Group Plc Purchases 23,716 Shares of BridgeBio Pharma, Inc. $BBIO

Guardant Health Insider Sold Shares Worth $5,846,163, According to a Recent SEC Filing

Guardant Health Insider Sold Shares Worth $5,846,163, According to a Recent SEC Filing

Monroe Terilyn J, an officer of Guardant Health Inc, sold 55,167 shares worth $5.8 million as disclosed in a Form 4 filed with the SEC on December 3, 2025. The sale was executed under a prearranged trading plan (10b5-1).

Officer Monroe Sells 55,167 ($5.8M) Of Guardant Health Inc [GH]

NTRA

Natera's CEO and President, Steven Leonard Chapman, and President of Clinical Diagnostics, Solomon Moshkevich, both sold shares of the company's common stock on December 1, 2025. Chapman sold 4,400 shares for $1,047,501, reducing his ownership to 140,416 shares. Moshkevich sold 3,000 shares for $714,458, reducing his ownership to 109,061 shares. Both transactions were executed under Rule 10b5-1 trading plans.

TradingView

Natera

Natera Executives Engage in Stock Sales

Moshkevich Solomon Officer of Natera Inc [NTRA] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/1/25TransactionPlanned Sale(1) Shares3,000Price$238.15Value$714,459Ending Holdings: 109,061 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Moshkevich Sells 3,000 ($714.5K) Of Natera Inc [NTRA]

Solomon Moshkevich, President of Clinical Diagnostics at Natera Inc., reported the sale of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

Natera President of Clinical Diagnostics Solomon Moshkevich Reports Sale of Common Shares

Natera Inc.'s CEO and President, Steven Leonard Chapman, has reported the disposal of common shares of the company. The details are available in the filing on EDGAR, the SEC's system. This announcement is informational and not financial advice.

Natera CEO and President Steven Leonard Chapman Reports Disposal of Common Shares

Medpace Holdings Insider Sold Shares Worth $17,114,847, According to a Recent SEC Filing

Medpace Holdings Insider Sold Shares Worth $17,114,847, According to a Recent SEC Filing